Amendment No. 2 to Master Clinical Trial Collaboration AgreementMaster Clinical Trial Collaboration Agreement • February 28th, 2022 • Compugen LTD • Biological products, (no disgnostic substances)
This Amendment No. 2 to Master Clinical Trial Collaboration Agreement (this “Amendment”) is effective as of February 19, 2021 (“Amendment Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENTMaster Clinical Trial Collaboration Agreement • February 28th, 2022 • Compugen LTD • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT (this “Amendment”) is effective as of February 14, 2020 (“Amendment Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENTMaster Clinical Trial Collaboration Agreement • February 20th, 2020 • Compugen LTD • Biological products, (no disgnostic substances) • New York
THIS AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT (this “Amendment”) is effective as of February 14, 2020 (“Amendment Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
Amendment No. 3 to Master Clinical Trial Collaboration AgreementMaster Clinical Trial Collaboration Agreement • November 12th, 2021 • Compugen LTD • Biological products, (no disgnostic substances)
This Amendment No. 3 to Master Clinical Trial Collaboration Agreement (this “Amendment No. 3”) is effective as of November 10, 2021 (“Amendment No. 3 Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
MASTER CLINICAL TRIAL COLLABORATION AGREEMENTMaster Clinical Trial Collaboration Agreement • March 29th, 2021 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS MASTER CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of December 7, 2020 (the “Effective Date”) by and between Checkmate Pharmaceuticals, Inc., a Delaware corporation headquartered at 245 Main Street, Cambridge, MA 02142 (“Checkmate”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, New York. 10016 (“BMS”). Checkmate and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” MASTER...Master Clinical Trial Collaboration Agreement • November 4th, 2022 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
This Master Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into as of as of the date signed by the last Party to sign below (the “Effective Date”) by and between BioAtla, Inc., headquartered at 11085 Torreyana Road, San Diego, California 92121 (the “Company”), and Bristol-Myers Squibb Company, headquartered at 430 E. 29th Street, 14FL, New York, New York. 10016 (“BMS”). The Company and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
MASTER CLINICAL TRIAL COLLABORATION AGREEMENTMaster Clinical Trial Collaboration Agreement • November 7th, 2018 • Compugen LTD • Biological products, (no disgnostic substances) • New York
The Parties desire to agree on the following terms in order to develop innovative medicines as promptly as reasonably practicable, to avoid intellectual property and other conflicts with Third Parties in related subject matter transactions, and to better ensure that each Party focuses its efforts on the development of an appropriate Combined Therapy Clinical Trial and that the agreed-upon Combined Therapy Clinical Trial proceed in an effective, cost-efficient and timely manner:
Amendment No. 3 to Master Clinical Trial Collaboration AgreementMaster Clinical Trial Collaboration Agreement • February 28th, 2022 • Compugen LTD • Biological products, (no disgnostic substances)
This Amendment No. 3 to Master Clinical Trial Collaboration Agreement (this “Amendment No. 3”) is effective as of November 10, 2021 (“Amendment No. 3 Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. FIRST...Master Clinical Trial Collaboration Agreement • March 23rd, 2023 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
This First Amendment to the Master Clinical Trial Collaboration Agreement (this “First Amendment”) is entered into on October 14, 2022 (“the First Amendment Effective Date”) by and between Bristol-Myers Squibb Company with offices located at Route 206 and Province Line Road, Princeton, NJ 08543-4000 (“BMS”) and BioAtla, Inc., headquartered at 11085 Torreyana Road, San Diego, California 92121 (the “Company”). Each of BMS and the Company are individually referred to herein as a “Party” and collectively as the “Parties”.
